1. Hawkins MJ, Levin M, Borden EC. An ECOG phase I-II pilot study of polyriboinosinicpolyribocytidylic acid poly-L-Lysine complex (Poly ICLC) in patients with metastatic malignant melanoma. J Biol Response Mod 1985; 4: 664–668.
2. Litton G, Hong R, Grossberg SE, Echlekar D, Goodavish CN, Borden EC. Biological and clinical effects of the oral immunomodulator 3,6-bis (2-piperidinoethoxy) acridine trihydrochloride in patients with advanced malignancy. J Biol Response Mod 1990; 9: 61–70.
3. Rios A, Stringfellow DA, Fitzpatrick FA, et al. Phase I study of 2-amino-5bromo-6-phenyl4 (eH)-pyrimidinone (ABPP), an oral interferon inducer, in cancer patients. JBiol Response Mod 1986; 5: 330–338.
4. Urba WJ, Longo DL, Weiss RB. Enhancement of natural killer activity in human peripheral blood by flavone acetic acid. J Natl Cancer Inst 1988; 80: 521–525.
5. Goldstein D, Hertzod P, Tomkinson E, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998; 178: 858–861.